Business Daily Media

The Times

.

Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board

  • Written by PR Newswire
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board

PERTH, Australia, July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company with NovaCina[1] CDMO division and LumaCina[2] pharmaceutical supply division, announces the addition of renown Australian executive John Van Der Wielen to Board of Directors. Van Der Wielen will focus on Australian expansion programs for all three entities.

Renown Australian executive John Van Der Wielen joins Board of Directors for Bridgewest Perth Pharma. Renown Australian executive John Van Der Wielen joins Board of Directors for Bridgewest Perth Pharma.

Van Der Wielen brings a wealth of global experience and strategic insight to the Board, globally and within Australia. His extensive accomplishments in corporate strategy across diverse industries, including the health industry, plus his proven track record of driving growth and innovation, makes him a valuable asset to the company's leadership team.

"John's appointment to our board marks a significant milestone for Bridgewest Perth Pharma," said Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group. "His expertise will be instrumental as we continue to expand our operations and explore new opportunities within the pharmaceutical sector. We are thrilled to welcome John to our team and look forward to his contributions in guiding our strategic direction."

Van Der Wielen is currently the Chair for Orthocell Ltd. and Crown Resorts Perth. Previously, he was Chair of the Future Health Innovation and Research Fund WA, Director at Royal Flying Doctor Service (WA), and CEO of one of Australia's largest health insurance funds.

 "I am very excited to be involved with Bridgewest Group and Bridgewest Perth Pharma," said Van Der Wielen. Bridgewest Group, the private equity company behind Bridgewest Perth Pharma, has been a major life science and biotech investor globally. Among its recent investments in Australia is the Pfizer Perth facility, which is bringing about new pharma manufacturing jobs to Perth as well as needed drug supplies to the region. "I share their passion to grow this important sector, creating thousands of scientific jobs. The potential for Bridgewest Perth Pharma to play a critical role in broadening Australia business economy, adding leading global exporter of quality medical products, is an amazing opportunity. With a commitment to excellence and a passion for innovation, Bridgewest Perth Pharma will push the boundaries of what is possible in healthcare," added Van Der Wielen.

About Bridgewest GroupBridgewest Group [3]is an innovative and privately held global investment firm with over $3B in private capital. Founded in 1999, the global firm has earned a long-standing reputation for creating and scaling transformational businesses to achieve outsized success. Bridgewest Group leverages its expertise and global eco-community in key sectors where it can have the greatest impact including Life Sciences, Software, Semiconductor and Artificial Intelligence/Deep Tech. Customized financial investment services and diverse real estate holdings augment equity assets and support portfolio companies as they grow. Bridgewest Group is based in the US, with investments primarily in the US, Europe, China, Australasia and India.

About Bridgewest Perth Pharma Bridgewest Perth Pharma is a global pharmaceutical company, wholly owned by private investment firm Bridgewest Group. It operates through its two divisions, NovaCina, the company's CDMO, and LumaCina, the company's pharmaceutical marketing and supply division. Bridgewest Perth Pharma brings together innovative life sciences and talented people to meet the escalating demand for high quality drug manufacturing and therapeutics. For more information, visit: https://bridgewestperthpharma.com.au/[4][5]

Media Contact: Jenny Bourbiel, jbourbiel@bridgewestgroup.com[6]

Photo - https://mma.prnasia.com/media2/2451263/Bridgewest_Perth_Pharma_John_Van_Der_Weilen.jpg?p=medium600Logo - https://mma.prnasia.com/media2/2253875/4789527/BWP_Logo_Color_1600px_Logo.jpg?p=medium600[7][8]

Read more https://www.prnasia.com/story/archive/4451721_AE51721_0

Why self-service is reshaping fleet management for modern businesses

Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...

Fraud Prevention and security crucial as identity crime hits record highs in Australia

In a radically transformed risk landscape where the scale and speed of financial fraud have reached unprecedented levels, Australian businesses ar...

Sectorial ATO Tax Debt Disclosures Rise, Overall Business Credit Demand Flattens and High-Risk SME 'Credit Shopping' hits 8-month peak

Q1 2026 Equifax Business Market Pulse shows low-risk borrowers consolidate demand enquiries while sub-prime entities accelerate shopping activity ...

SME support in Federal Budget falls short of easing business pressures

“The Federal Budget delivered several measures aimed at supporting small businesses, including making the instant asset write-off permanent, exten...

Bunji dog treats to hit Ritchies shelves

Cooee Native Superfoods’ Bunji range of dog kibble and treats is rolling out across Ritchies Supermarkets now, with stock already on shelves in se...

Pre-Budget Expectations

“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...